TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20880642

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural menopausal supplements and diets rich in isoflavones
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paroxetine, fluoxetine, bupropion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluvoxamine and nefazodone
Number of subjects: 0
Study: 18035078

Group type: EXPERIMENTAL
Intervention: Enoxaparin (up to 8 days)
Number of subjects: 3060

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) (48 hours)
Number of subjects: 3060
Study: 16192448

Group type: EXPERIMENTAL
Intervention: 30-microg dose of technetium-99m-labeled monodisperse albuterol aerosols with particle sizes of 1.5 microm, 3 microm, and 6 microm
Number of subjects: 12

Group type: COMPARATOR
Intervention: 200 microg metered-dose inhaler (MDI) albuterol
Number of subjects: 12
Study: 12270622

Group type: EXPERIMENTAL
Intervention: Moulded isomalt-based tablet (50 mg HCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moulded isomalt-based lozenge (50 mg HCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional tablet (Dichlotride 50 mg)
Number of subjects: 0
Study: 9857997

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 211

Group type: COMPARATOR
Intervention: No PCI (Control)
Number of subjects: 211
Study: 7637152

Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl continuous infusion (BF-C group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Morphine bolus injection (M-S group)
Number of subjects: 100
Study: 2474109

Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg initially, adjusted between 1.25-20 mg)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Ramipril plus HCT (25 mg)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Control group (captopril, HCT, atenolol)
Number of subjects: 331
Study: 320996

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol proprionate (CP)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cream base alone
Number of subjects: 23
Study: 30953553

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition
Number of subjects: 151

Group type: COMPARATOR
Intervention: Parenteral Nutrition
Number of subjects: 151
Study: 28364509

Group type: EXPERIMENTAL
Intervention: Almorexant 200 mg
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Almorexant 100 mg
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Almorexant 50 mg
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Almorexant 25 mg
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Almorexant (all doses)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 26925577

Group type: EXPERIMENTAL
Intervention: AAB-003 (0.5, 1, 2, 4, or 8 mg/kg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: AAB-003 (8 mg/kg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: AAB-003
Number of subjects: 88
Study: 25079882

Group type: EXPERIMENTAL
Intervention: Nurse delivered intervention with intensive training on screening for IPV, providing supportive referrals, and assessing health and safety risks.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard of care with a one-day training focused on sensitizing staff to IPV as a health issue and referral cards.
Number of subjects: 42
Study: 22527308

Group type: EXPERIMENTAL
Intervention: Bibrocathol 2% eye ointment
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 19745175

Group type: EXPERIMENTAL
Intervention: 3 g/day encapsulated fish oil (1.2 g total omega-3: 0.7 g DHA; 0.3 g EPA)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo oil (combination palm and soy)
Number of subjects: 102
Study: 17688396

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 325
Study: 15122605

Group type: EXPERIMENTAL
Intervention: Miller vein cuff
Number of subjects: 235

Group type: COMPARATOR
Intervention: Non-cuffed bypasses
Number of subjects: 235
Study: 11260813

Group type: EXPERIMENTAL
Intervention: Increasing the inter‐cigarette interval
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Selecting easy cigarettes to eliminate
Number of subjects: 20
Study: 9626787

Group type: EXPERIMENTAL
Intervention: Low-dose leucovorin (20 mg/m2/day, days 1 through 5) combined with 5-FU (400 mg/m2/day every 4 weeks)
Number of subjects: 83

Group type: COMPARATOR
Intervention: High-dose leucovorin (200 mg/m2/day, days 1 through 5) combined with 5-FU (400 mg/m2/day every 4 weeks)
Number of subjects: 83

Group type: COMPARATOR
Intervention: High-dose leucovorin combined with 5-FU
Number of subjects: 83
Study: 7886280

Group type: EXPERIMENTAL
Intervention: High frequency physical guidance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High frequency feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knowledge of results
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faded relative frequency
Number of subjects: 0
Study: 3312283

Group type: EXPERIMENTAL
Intervention: Micronized oral progesterone, 200 mg daily
Number of subjects: 5
Study: 29921036

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) and lattice CO2 laser treatments
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional approach with scar cream massage and silica gel products
Number of subjects: 50
Study: 26910108

Group type: EXPERIMENTAL
Intervention: Bromocriptine mesylate (BRC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 25135744

Group type: EXPERIMENTAL
Intervention: 6 SQ HDM SLIT-tablet
Number of subjects: 604

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604
Study: 21782418

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (CRT) (2Gyx25+5FU/leucovorin)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Radiotherapy (RT) (2Gyx25)
Number of subjects: 207
Study: 20841796

Group type: EXPERIMENTAL
Intervention: Email reminders focused on intervention related content (smoking cessation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Email reminders focused on general project announcements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Email reminders focused on unrelated content (oral cancer prevention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day of the week for sending emails
Number of subjects: 0
Study: 18048572

Group type: EXPERIMENTAL
Intervention: Oral unfractionated heparin with sodium N‐[8‐(2‐hydroxybenzoyl) amino]caprylate (salcaprozate sodium, SNAC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Parenterally administered unfractionated heparin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral unfractionated heparin with SNAC
Number of subjects: 16
Study: 16264035

Group type: EXPERIMENTAL
Intervention: BALF smear
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: BALF PCR
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: BALF smear and/or PCR
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: BALF smear or Mycobacterium tuberculosis complex‐PCR
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Combined use of BALF smear and Mycobacterium tuberculosis complex‐PCR
Number of subjects: 230
Study: 12019380

Group type: EXPERIMENTAL
Intervention: Hypothermic circulatory arrest with retrograde cerebral perfusion
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hypothermic circulatory arrest alone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 7585864

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 164

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 164
Study: 2223344

Group type: EXPERIMENTAL
Intervention: Topical 5% EMLA cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo cream and 1% lignocaine infiltration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EMLA and 0.9% saline infiltration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EMLA and 1% lignocaine infiltration
Number of subjects: 40
Study: 353090

Group type: EXPERIMENTAL
Intervention: Anisotropine methyl bromide, 80 mg given orally at 8 P.M.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Anisotropine methyl bromide
Number of subjects: 30
Study: 30702534

Group type: EXPERIMENTAL
Intervention: Oral diclofenac potassium (50 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous acetaminophen (1 g in 500 ml normal saline over 20 min)
Number of subjects: 60
Study: 28826727

Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon (DEB) with provisional bare-metal stenting
Number of subjects: 254

Group type: COMPARATOR
Intervention: Primary stenting with drug-eluting stents (DES)
Number of subjects: 254
Study: 26764322

Group type: EXPERIMENTAL
Intervention: Aged Garlic Extract (AGE) 2400 mg/d
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 23652947

Group type: EXPERIMENTAL
Intervention: 1% retinol
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 0.5% retinol
Number of subjects: 41

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 41
Study: 21270270

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Adrenergic blockade (phentolamine and propranolol)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Adrenergic blockade plus cholinergic blockade (atropine)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline infusion on day 2
Number of subjects: 17
Study: 19161864

Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (iNO)
Number of subjects: 0
Study: 17952474

Group type: EXPERIMENTAL
Intervention: Intraoperative hypnosis
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard treatment without hypnosis
Number of subjects: 70
Study: 15514725

Group type: EXPERIMENTAL
Intervention: Extract of Rhodiola rosea radix
Number of subjects: 0
Study: 11703529

Group type: EXPERIMENTAL
Intervention: Topical aspirin (75 mg/mL in moisturizer, 5-10 mL, three times a day for 21 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral aspirin (375-750 mg three times a day for 21 days)
Number of subjects: 30
Study: 9718524

Group type: EXPERIMENTAL
Intervention: Open invitation asking women to telephone the screening unit for another appointment
Number of subjects: 2229

Group type: COMPARATOR
Intervention: Fixed appointment time
Number of subjects: 2229
Study: 8005127

Group type: EXPERIMENTAL
Intervention: Oral enoximone (100 mg t.i.d.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral enoximone
Number of subjects: 24
Study: 2805771

Group type: EXPERIMENTAL
Intervention: 100 mg trazodone conventional capsules
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 150 mg controlled‐release tablets
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both formulations of trazodone
Number of subjects: 14
Study: 1103708

Group type: EXPERIMENTAL
Intervention: Alprenolol (200 mg twice daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 19
Study: 31262103

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-induced sleep
Number of subjects: 47
Study: 27939053

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) environment with cooperative social feedback
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) environment with rejective social feedback
Number of subjects: 26

Group type: COMPARATOR
Intervention: Virtual reality (VR) environment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 26
Study: 24840246

Group type: EXPERIMENTAL
Intervention: Laminotomy
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: Hemilaminectomy
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: Laminectomy
Number of subjects: 1176

Group type: COMPARATOR
Intervention: Laminectomy with Instrumented Fusion (IF)
Number of subjects: 1176
Study: 23880426

Group type: EXPERIMENTAL
Intervention: Iopromide 300 mg/ml with fixed-dose injection protocol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Iopromide 300 mg/ml with body surface area adapted injection protocol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Iopromide 370 mg/ml with fixed-dose injection protocol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Iopromide 370 mg/ml with body surface area adapted injection protocol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-enhanced PET/CT
Number of subjects: 120
Study: 21825259

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily orally until disease progression (PD) occurred
Number of subjects: 143

Group type: COMPARATOR
Intervention: Chemotherapy with paclitaxel 200 mg/m2 IV and carboplatin AUC 6 IV on day 1 intercalated with erlotinib 150 mg orally on days 2 through 15 every 3 weeks for four cycles followed by erlotinib 150 mg orally until PD occurred
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Erlotinib alone
Number of subjects: 143

Group type: COMPARATOR
Intervention: CT + erlotinib
Number of subjects: 143
Study: 19741514

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16700816

Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg daily for 5 days)
Number of subjects: 9
Study: 15537474

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 242
Study: 11303851

Group type: EXPERIMENTAL
Intervention: Cefepime (50 mg/kg/dose every 8 h; ≤ 6 g/day)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Ceftazidime (50 mg/kg/dose every 8 h; ≤ 6 g/day)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 104

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cefepime and Ceftazidime
Number of subjects: 104
Study: 9423752

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Narcotics
Number of subjects: 100
Study: 7740445

Group type: EXPERIMENTAL
Intervention: Recombinant tissue factor (RTF)
Number of subjects: 757

Group type: COMPARATOR
Intervention: Conventional thromboplastin (CT)
Number of subjects: 757
Study: 3402097

Group type: EXPERIMENTAL
Intervention: Prophylactic systemic antibiotics
Number of subjects: 130

Group type: COMPARATOR
Intervention: Non-antibiotic group
Number of subjects: 130
Study: 31732485

Group type: EXPERIMENTAL
Intervention: B200PaZ
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: BloadPaZ
Number of subjects: 240

Group type: COMPARATOR
Intervention: HRZE
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Drug-susceptible tuberculosis
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Rifampicin-resistant tuberculosis
Number of subjects: 240
Study: 28073798

Group type: EXPERIMENTAL
Intervention: Postural monitoring and feedback device (PMF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-feedback control group
Number of subjects: 0
Study: 25923552

Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy
Number of subjects: 1375

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1375
Study: 22816881

Group type: EXPERIMENTAL
Intervention: Acitretin 25 mg/day
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Acitretin 35 mg/day
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Acitretin 50 mg/day
Number of subjects: 61
Study: 20971644

Group type: EXPERIMENTAL
Intervention: Stoopwalking
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Four-point crawling
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Two-point crawling
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: EMG findings for knee extensors and flexors during all gait techniques
Number of subjects: 9

Group type: COMPARATOR
Intervention: Presence or absence of kneepads
Number of subjects: 9
Study: 18276652

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 50 mg kg(‐1) i.v. as a bolus and then 15 mg kg(‐1) h(‐1) i.v. by continuous infusion
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 50
Study: 16949484

Group type: EXPERIMENTAL
Intervention: Concordant treatment allocation
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Discordant treatment allocation
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in discordant patients
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Clinical judgment
Number of subjects: 611
Study: 12641601

Group type: EXPERIMENTAL
Intervention: VbX+ (squatting exercise with vibration)
Number of subjects: 19

Group type: COMPARATOR
Intervention: VbX- (squatting exercise without vibration)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: VbX+
Number of subjects: 19

Group type: COMPARATOR
Intervention: VbX-
Number of subjects: 19
Study: 10671664

Group type: EXPERIMENTAL
Intervention: FPLC chemotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no FPLC chemotherapy)
Number of subjects: 60
Study: 9174182

Group type: EXPERIMENTAL
Intervention: Cefmenoxime
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ciprofloxacin or Ceftazidime
Number of subjects: 43
Study: 8445428

Group type: EXPERIMENTAL
Intervention: Delayed intensification (Delint) phase of therapy
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Standard three-drug induction and Delint
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (IT MTX) during all phases of therapy
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Intensive induction, Delint, and CXRT
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 1600
Study: 3731891

Group type: EXPERIMENTAL
Intervention: Liquid meal of 317 kcal (group 1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo medication (group 2)
Number of subjects: 32
Study: 29402570

Group type: EXPERIMENTAL
Intervention: Asthma question prompt list with video intervention
Number of subjects: 359

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 359
Study: 26501498

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral conjoint therapy (CBCT) for PTSD
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 39
Study: 24794367

Group type: EXPERIMENTAL
Intervention: Fluconazole (6 mg/kg of body weight)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study: 24330669

Group type: EXPERIMENTAL
Intervention: Early childhood caries (ECC) intervention consisting of dental care during pregnancy, fluoride varnish application, motivational interviewing, and anticipatory guidance.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 0
Study: 22167034

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration with collagen membrane (CM) combined with autogenous bone graft (test group 1)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration with collagen membrane (CM) combined with autogenous bone mixed with bioactive glass (test group 2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Guided tissue regeneration with collagen membrane (CM) alone (control group)
Number of subjects: 22
Study: 18498033

Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate (ATP) stress
Number of subjects: 38

Group type: COMPARATOR
Intervention: Exercise stress
Number of subjects: 38
Study: 16739748

Group type: EXPERIMENTAL
Intervention: Permanent prostate brachytherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supplemental external-beam radiation therapy (XRT)
Number of subjects: 0
Study: 14668071

Group type: EXPERIMENTAL
Intervention: Nicotine (20 microg/kg) administered by nasal spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10901307

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 10929

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 10929

Group type: EXPERIMENTAL
Intervention: Any prophylactic agent
Number of subjects: 10929

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 10929

Group type: EXPERIMENTAL
Intervention: Pneumatic compression
Number of subjects: 10929
Study: 8642235

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention for 2 years
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Multifactorial intervention and Control group
Number of subjects: 149
Study: 1519588

Group type: EXPERIMENTAL
Intervention: Prednisolone (50 mg/day) for 1 month
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 6375329

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 29
Study: 30847753

Group type: EXPERIMENTAL
Intervention: Fear appeals (low, moderate, high)
Number of subjects: 117
Study: 29629603

Group type: EXPERIMENTAL
Intervention: EMLA cream applied for 30 minutes
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: EMLA cream applied for 60 minutes
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 361
Study: 26698015

Group type: EXPERIMENTAL
Intervention: Power-based resistance training (PWT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 26
Study: 25168927

Group type: EXPERIMENTAL
Intervention: Prophylactic haloperidol 1 mg twice daily for a maximum of seven consecutive days
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Prophylactic haloperidol
Number of subjects: 390
Study: 22901557

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (Omacor, 3 g/d) for 6 months
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 47
Study: 21144033

Group type: EXPERIMENTAL
Intervention: Health education sessions for residents in their homes, appointment of a health ambassador among the staff, and a study circle for staff in each residence.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in work routines in the residences assessed by a questionnaire to managers.
Number of subjects: 0